Facebook Twitter LinkedIn Google Plus RSS

Eisai gets $65M for U.S. rights to Targretin

By ,

Eisai Inc.’s U.S. operations announced today that it sold the U.S. rights to its Targretin capsules and gel to Montreal-based Valeant Pharmaceuticals International Inc.

Eisai, in Woodcliff Lake, received $65 million up front, plus potential future payments based on certain milestones. Valeant assumes responsibilities for all regulatory obligations associated with the product in the United States.

 

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!